Lippoldt Darin 4

What Happened
Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences (NBIX), had 2,373 restricted stock units (RSUs) vest on January 31, 2026 and converted into 2,373 shares. To satisfy tax withholding, 1,335 shares were withheld (valued at $136.06/share) for a tax withholding amount of $181,640. That leaves a net issuance to Lippoldt of approximately 1,038 shares. This was a standard vesting/settlement of RSUs (compensation), not an open-market purchase or investment sell.

Key Details

• Transaction date: January 31, 2026; Form filed February 3, 2026. No late filing was indicated.
• Reported codes: M = exercise/conversion of derivative (RSU converted to shares); F = shares withheld for tax withholding.
• Shares involved: 2,373 RSUs vested → 2,373 shares issued; 1,335 shares withheld for taxes at $136.06/share (= $181,640); net ~1,038 shares retained.
• Price reported for conversion entries: $0.00 (typical for RSU settlement reporting). Withholding price used: $136.06.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: Shares were withheld by the company to satisfy tax withholding on RSU vesting (no shares were sold). The RSU award was granted Jan 31, 2022 and vested in four equal tranches of 2,373 shares on Jan 31 of 2023–2026.

Context
This was a routine RSU vesting/settlement (compensation event). The withholding of shares to cover taxes is common and should not be interpreted as a market sale or a directional trade signal. The filing shows conversion of RSUs to shares and withholding for taxes rather than an open-market sale or purchase.